Therapeutic Bispecific T-Cell Engager Antibody Targeting The Intracellular Oncoprotein WT1
Eureka’s co-authored paper “Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1,” was published on Monday in Nature Biotechnology. The paper describes a bispecific antibody against intracellular antigen (WT-1) that can cross-prime T cells against new antigens, thus spreading epitopes. The study was performed in collaboration with Memorial Sloan Kettering Cancer Center.
Read the article here: www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.3349.html